Central Nervous System Progression in Patients Receiving ALK-Targeted Central Nervous System–Penetrable Tyrosine Kinase Inhibitors: Treatment Patterns and Outcomes
For patients with <i>ALK-</i>rearranged NSCLC with leptomeningeal progression or concurrent systemic progression, TKI change or dose increase was a feasible salvage strategy for CNS progression during treatment with CNS-penetrable TKI.
Authors
- Surbhi Singhal (ORCID: https://orcid.org/0000-0003-4307-319X)
- Kavitha Ramchandran (ORCID: https://orcid.org/0000-0002-9033-819X)
- Caressa Hui (ORCID: https://orcid.org/0000-0002-3864-4720)
- Seema Nagpal (ORCID: https://orcid.org/0000-0002-0289-2319)
- Giovanni Selvaggi (ORCID: https://orcid.org/0000-0001-8015-8999)
- Joel W. Neal (ORCID: https://orcid.org/0000-0003-3119-9334)
- Heather A. Wakelee (ORCID: https://orcid.org/0000-0003-1136-980X)
- Millie Das (ORCID: https://orcid.org/0000-0001-6678-9743)
- Mohana Roy (ORCID: https://orcid.org/0000-0002-9997-8935)
- Erqi Liu Pollom (ORCID: https://orcid.org/0000-0003-2908-6293)
- Nathaniel J. Myall
Institutions
- University of California, Irvine (US)
- VA Palo Alto Health Care System (US)
- Xcovery (United States) (US)
- University of California Davis Medical Center (US)
- University of California, Davis (US)
- Stanford University (US)
Publication Details
- Journal
- JTO Clinical and Research Reports
- Published
- 2025-10-04
- DOI
- https://doi.org/10.1016/j.jtocrr.2025.100914
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00